ARS Pharmaceuticals (SPRY) to Release Quarterly Earnings on Thursday

ARS Pharmaceuticals (NASDAQ:SPRY) is projected to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.4765) per share and revenue of $31.3320 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.08). ARS Pharmaceuticals had a negative net margin of 200.00% and a negative return on equity of 153.61%. The company had revenue of $22.68 million for the quarter, compared to analysts’ expectations of $22.20 million. On average, analysts expect ARS Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ARS Pharmaceuticals Stock Performance

Shares of SPRY stock opened at $5.95 on Wednesday. The company has a quick ratio of 4.77, a current ratio of 4.94 and a debt-to-equity ratio of 2.79. The company has a 50 day moving average price of $7.75 and a 200-day moving average price of $8.39. ARS Pharmaceuticals has a 52 week low of $4.91 and a 52 week high of $17.46. The firm has a market capitalization of $590.84 million, a PE ratio of -2.96 and a beta of 0.98.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Leerink Partners dropped their target price on shares of ARS Pharmaceuticals from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Thursday, June 25th. Wall Street Zen upgraded shares of ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Cantor Fitzgerald increased their price target on ARS Pharmaceuticals from $12.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 28th. Finally, Weiss Ratings upgraded ARS Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 1st. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $28.20.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, insider Alexander A. Fitzpatrick sold 3,355 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $10.00, for a total value of $33,550.00. Following the completion of the sale, the insider owned 90,910 shares in the company, valued at $909,100. This represents a 3.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Karas sold 25,000 shares of the firm’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $10.00, for a total value of $250,000.00. Following the completion of the transaction, the insider directly owned 12,176 shares in the company, valued at $121,760. This trade represents a 67.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 33.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Creek Drive Management Group LLC purchased a new stake in ARS Pharmaceuticals in the 4th quarter worth approximately $3,447,000. FAS Wealth Partners Inc. lifted its holdings in ARS Pharmaceuticals by 0.9% during the fourth quarter. FAS Wealth Partners Inc. now owns 202,407 shares of the company’s stock valued at $2,358,000 after purchasing an additional 1,787 shares in the last quarter. VARCOV Co. purchased a new position in ARS Pharmaceuticals during the fourth quarter valued at approximately $260,000. Osterweis Capital Management Inc. bought a new position in shares of ARS Pharmaceuticals in the fourth quarter worth approximately $65,000. Finally, Millennium Management LLC bought a new position in shares of ARS Pharmaceuticals in the fourth quarter worth approximately $36,912,000. 68.16% of the stock is currently owned by institutional investors.

More ARS Pharmaceuticals News

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Negative Sentiment: Multiple firms, including Pomerantz, Rosen, Bronstein Gewirtz & Grossman, Kaplan Fox, and others, said a securities class action has been filed on behalf of investors who purchased ARS Pharmaceuticals securities between March 9 and June 24, 2026. The suit alleges violations of federal securities laws, although the notices do not provide detailed findings or establish liability. Pomerantz investor alert
• Negative Sentiment: Investors affected during the class period were repeatedly encouraged to contact law firms about seeking lead-plaintiff status. The stated deadline to petition for appointment as lead plaintiff is October 5, 2026, keeping the litigation in the market’s focus in the near term. Faruqi shareholder action reminder
• Neutral Sentiment: The numerous announcements largely repeat the same lawsuit and deadline information rather than reporting a new operating or regulatory development. Their volume may amplify headline risk, but the notices alone do not determine the lawsuit’s outcome or quantify potential damages.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.